New drug has potential to treat broader range of cancers

New drug has potential to treat broader range of cancers

(Medical Xpress)—ImmuNext, founded by scientists at King's College London, has announced a  research and drug development agreement with Janssen Biotech Inc to develop a new cancer drug to trigger the body's own immune system to fight the disease.

The new therapy will be based on a discovery made by scientists at the MRC Centre for Transplantation at King's and Dartmouth Medical School (US), who identified a novel molecule in the immune system called VISTA, thought to be key to unlocking the body's own cancer-fighting response.

The NIHR Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust and King's College London provided support to the project carried out at King's, which uncovered the role of  VISTA. VISTA naturally suppresses the immune system's response to and  limits a person's ability to kick-start the response needed to attack the disease. Drugs that block the function of VISTA have proven in pre-clinical models to enhance cancer immunity and reduce . It is anticipated that blocking VISTA in will allow the body to trigger a protective immune response to cancer with the ultimate goal of .

While there are already drugs in early development to unlock the body's own immune system to attack cancer cells, it is thought that the inhibition of VISTA has the potential to treat a much broader range of solid and liquid cancers.

ImmuNext will grant Janssen a worldwide exclusive license to develop and commercialise therapies that suppress VISTA.

Professor Randolph Noelle, MRC Centre for Transplantation at King's and Chief Scientific Officer at ImmuNext, said: 'This is an extremely exciting development in the fight against cancer. We have discovered a new that could allow us to unleash a patient's own immune response to attack and eradicate the disease.

'We are delighted to be working with Jenssen to turn this discovery into real treatments for cancer patients.

'Immunotherapy has taken centre stage in the cure for cancer, and VISTA represents the newest, and one of the most exciting novel targets in this approach.'

Related Stories

Immune cell can trigger skin cancer caused by toxins

date Jan 09, 2012

(Medical Xpress) -- Researchers based jointly at King’s College London and the Cancer Research UK London Research Institute, together with collaborators at Yale University have found that a type of immune ...

Study: Tumors inhibit immune system

date May 29, 2006

Seattle scientists have shown that tumors can manipulate the immune system to stop it from attacking cancer cells, said a study published in Nature Immunology.

Recommended for you

Experts set strategic priorities for lymphoma research

date 6 hours ago

A committee of lymphoma experts today unveiled a strategic roadmap identifying key priority areas in both infrastructure and research that will be critical for advancing treatments for people with lymphoma. The report is meant to inform future research directions as well as fund ...

Research aims to reduce health care disparities

date 6 hours ago

The lesbian, gay, bisexual, transgender/transsexual, queer/questioning and intersex (LGBTQI) population has been largely understudied by the medical community. Researchers at Moffitt Cancer Center found that the LGBTQI community ...

Promising drug target identified in medulloblastoma

date 7 hours ago

Scientists at Dana-Farber/Boston Children's Cancer and Blood Disorders Center have identified a protein critical to both the normal development of the brain and, in many cases, the development of medulloblastoma, a fast-growing ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.